P.07.36 REAL-WORLD EVIDENCE OF VEDOLIZUMAB THERAPY IN ULCERATIVE COLITIS AND CROHN'S DISEASE PATIENTS: FECAL CALPROTECTIN A VALID BIOMARKER OF MUCOSAL INFLAMMATION

Autor:	I Luppino, P. Leo, P. Paese, C Cicerone, M. Erboso
Rok vydání:	2019
Předmět:	medicine.medical_specialty Crohn's disease Hepatology business.industry Gastroenterology Mucosal inflammation Real world evidence medicine.disease Ulcerative colitis Vedolizumab Internal medicine Valid Biomarker medicine Calprotectin business Feces medicine.drug
Zdroj:	Digestive and Liver Disease. 51:e239
ISSN:	1590-8658
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::8809a28aed0bc43532af8442cf48c57b https://doi.org/10.1016/s1590-8658(19)30485-2 Zobrazit plný text záznamu Full Text from ScienceDirect